Adagio Therapeutics Reports First Quarter 2022 Financial Results

Provided By Globe Newswire

Last update: May 13, 2022

$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024

Additional Data from Adintrevimab Phase 2/3 STAMP Treatment Trial to be Presented at ASM Annual Meeting